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In the present study, we discuss the recent developments in oxysterol research. Exciting
results have been reported relating to the involvement of oxysterols in the ﬁelds of neuro-
degenerative disease, especially in Huntington’s disease, Parkinson’s disease and
Alzheimer’s disease; in signalling and development, in particular, in relation to Hedgehog
signalling; and in cancer, with a special focus on (25R)26-hydroxycholesterol. Methods for the
measurement of oxysterols, essential for understanding their mechanism of action in vivo,
and valuable for diagnosing rare diseases of cholesterol biosynthesis and metabolism are
brieﬂy considered.
Introduction
Oxysterols are oxidised forms of cholesterol or of its precursors (Figure 1) [1]. They include
1α,25-dihydroxyvitamin D3, the biologically active form of vitamin D3, 24S-hydroxycholesterol
(24S-HC), also known as cerebrosterol, the major cholesterol metabolite found in the brain [2],
25-hydroxycholesterol (25-HC) synthesised in macrophages as a result of bacterial or viral infection
[3,4] and 22R-hydroxycholesterol (22R-HC), the ﬁrst metabolite of cholesterol in the steroid hormone
biosynthesis pathway [5]. 7α-Hydroxycholesterol (7α-HC) is the ﬁrst member of the neutral pathway of
bile acid biosynthesis and (25R)26-hydroxycholesterol (26-HC also known as 27-hydroxycholesterol,
when C-25 is asymmetric stereochemistry is assumed to be 25R unless stated otherwise, see
Supplementary Table S1 for a list of common and systematic names) is the ﬁrst member of the acidic
pathway of bile acid biosynthesis [6]. In this review, we also include cholestenoic acids, where the
terminal carbon of the cholesterol side-chain has been oxidised to a carboxylic acid, in the ‘family’ of
oxysterols (Figure 1). In the present study, we will adopt the nomenclature system outlined by the
Lipid Maps consortium [7] and follow IUPAC naming rules regarding oxidation of the terminal
carbon of the sterol side-chain [8].
Oxysterols are bioactive molecules. The side-chain oxysterols, where oxidation has occurred in the
sterol side-chain, are established ligands to the liver X receptors (LXRα, NR1H3; LXRβ, NR1H2) [9],
inhibitors of the processing of SREBP-2 (sterol regulatory element-binding protein-2) to its active form
as the master transcription factor for expression of genes in the mevalonate pathway of cholesterol bio-
synthesis [10] and potent allosteric modulators of the N-methyl-D-aspartate (NMDA) receptors [11,12].
The side-chain and ring doubly oxidised cholesterol metabolites 7α,25-dihydroxycholesterol (7α,25-
diHC) and 7α,(25R)26-dihydroxycholesterol (7α,26-diHC, also called 7α,27-dihydroxycholesterol) are
ligands to the G protein-coupled receptor (GPCR) 183, also known as the Epstein–Barr virus-induced
gene 2 (EBI2), and guide immune cell migration of EBI2-expressing cells [13,14]. (25R)26-Hydroxy-
7-oxocholesterol (26H,7O-C, also called 7-keto-27-hydroxycholesterol), 7β,(25R)26-dihydroxycholesterol
(7β,26-diHC, also called 7β,27-dihydroxycholesterol), like the elusive 20S-hydroxycholesterol (20S-HC),
and also cholesterol, are ligands to Smoothened (SMO), a key protein of the Hedgehog (Hh) signalling
pathway, important for proper cell differentiation in embryonic tissue, and when misfunctioning can
lead to basal cell carcinoma in adults [15–17].
Measurement of oxysterols, including C27 acids, in the circulation or cerebrospinal ﬂuid (CSF) is of
value for the diagnosis of rare inborn errors of cholesterol transport, biosynthesis and metabolism
[18–25]; additionally, these measurements may have value for deﬁning biomarkers of disease progres-
sion, particularly important in the development of new therapeutics for neurodegenerative disease.
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Measurement of oxysterols
Oxysterols are usually measured by gas chromatography–mass spectrometry (GC–MS) methods incorporating
selected-ion monitoring [26,27] or liquid chromatography tandem–mass spectrometry (LC–MS/MS) methods
exploiting multiple reaction monitoring [28]. When an alkaline hydrolysis step is included, the total oxysterol
(non-esteriﬁed plus esteriﬁed) is measured. In the absence of hydrolysis, the non-esteriﬁed or ‘free’ molecules
are measured. While derivatisation is a pre-requisite for GC–MS studies, this is not so for LC–MS/MS studies,
although many workers have employed derivatisation to enhance sensitivity [19,21,22,29,30]. The extreme
diversity of isomeric oxysterols makes chromatographic separation challenging; this problem is accentuated by
the similar fragmentation patterns, in both GC–MS and LC–MS/MS of many epimers [30,31] (Figure 2).
Besides chromatographic separation, avoidance of ex vivo oxidation of sterols, especially cholesterol, to produce
non-endogenous oxysterols is another major challenge, particularly if cholesterol is not separated from endogen-
ous oxysterols at an early stage in the sample handling procedure. The inexperienced analyst needs to keep these
two points in mind when analysing oxysterols to avoid miss-identiﬁcation and inaccurate quantiﬁcation.
Neurodegenerative disease including amyotrophic lateral
sclerosis, hereditary spastic paraplegia type 5, Huntington’s
disease, Parkinson’s disease and Alzheimer’s disease
Amyotrophic lateral sclerosis (ALS): recent studies of serum/plasma and CSF of patients suffering from ALS
have revealed elevated levels of free (non-esteriﬁed) cholesterol in CSF from an ALS patient group in compari-
son with a control group without neurodegenerative disease [32,33]. Analysis of serum revealed that both
26-HC and 3β-hydroxycholest-5-en-(25R)26-oic acid (3β-HCA), two metabolites derived from the oxidation of
cholesterol by the enzyme cytochrome P450 27A1 (CYP27A1, cytochrome P450 family 27 subfamily A
member 1), were reduced in the ALS patient group, suggesting dysregulation, or a reduced activity, of this
enzyme is associated with ALS [32]. Importantly, Diekstra et al. [34] have identiﬁed CYP27A1 to be a susceptibility
gene for sporadic ALS in genome-wide association studies.
Hereditary spastic paraplegia type 5 (SPG5), like ALS, is a form of motor neuron disease, but unlike ALS, it is
a monogenic disease resulting from a deﬁciency in CYP7B1 (cytochrome P450 family 7 subfamily B member 1),
the oxysterol 7α-hydroxylase (Figure 1) [18,35]. In contrast with ALS, both free and total (esteriﬁed plus non-
esteriﬁed) 26-HC and 3β-HCA are elevated in concentration in both plasma/serum and CSF of SPG5 patients
[18,21,25,35]. Interestingly, at low-mM concentrations, the levels of total 26-HC measured in serum, this mol-
ecule is found to be toxic towards a motor neuron cell line, implicating it as a toxic, disease-causing, metabolite
in SPG5 [35]. Patients suffering from cerebrotendinous xanthomatosis (CTX), where CYP27A1 is deﬁcient, like
patients with SPG5, can present with motor dysfunction, and patients with both disorders are found to be deﬁ-
cient in the cholestenoic acid, 3β,7α-dihydroxycholest-5-en-(25R)26-oic acid (3β,7α-diHCA) [21].
Theoﬁlopoulos et al. [21] showed that this molecule is protective to oculomotor neurons through a mechanism
involving LXRs, suggesting that its deﬁciency in both CTX and SPG5 may be responsible, at least in part, for
the motor phenotype in these diseases. Interestingly, ACOX2 (acyl-CoA oxidase-2) deﬁciency, an inborn error
of cholesterol metabolism, like CTX can present with ataxia [36], but unlike CTX shows elevated levels in
serum/plasma of C27 acids with unusual 25S-stereochemistry [37], including 3β,7α-dihydroxycholest-
5-en-(25S)26-oic acid, the 25S-epimer of 3β,7α-diHCA, which has recently been shown to be less neuroprotec-
tive than the 25R-epimer [30]. Both 25S- and 25R-epimers are oxidised in the brain to their 3-oxo-4-ene
equivalents, and 7α-hydroxy-3-oxocholest-4-en-26-oic acid has been shown to be exported out of the brain
into the circulation against a concentration gradient due to the high afﬁnity of the acid to albumin [38,39].
Huntington’s disease (HD) is an autosomal-dominant neurodegenerative disease caused by an elongated poly-
glutamine repeat in the huntingtin protein [40]. HD presents in mid-life with neuropsychiatric and cognitive
defects. Once diagnosed, life expectancy is usually only a further 15–20 years. An excess of 36 CAG (DNA
codon for glutamine) repeats in exon 1 of the HTT (huntingtin) gene leads to disease penetrance and the inci-
dence of HD is ∼10 in 100 000 in western populations [40]. In mouse models of HD, there is good evidence
for reduced levels of cholesterol precursors in the striatum, the region showing atrophy in HD [41,42] and also
dysregulation of cholesterol biosynthetic genes in HD cell lines and mouse models [43,44]. In their study of the
YAC128 HD mouse model (transgenic line overexpressing human HTT with 128 glutamine residues), Valenza
et al. [41] found a reduction in lanosterol, lathosterol, desmosterol (ng/mg wet weight), cholesterol (mg/mg wet
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weight) and 24-HC (ng/mg wet weight), the major cerebral cholesterol metabolite, in the brain of 10-month-old
animals compared with wild-type animals (Supplementary Table S2). The plasma level of 24-HC was similarly
reduced in 10-month-old YAC128 mice [41]. Using a second HD mouse model, R6/2, Valenza et al. [42]
found levels of lanosterol to be reduced (ng/mg wet weight) in the striatum, but surprisingly, levels of choles-
terol and of 24-HC did not differ in the striatum of the R6/2 mouse compared with wild-type animals. In a
further study, Valenza et al. [44] conﬁrmed that brain cholesterol and lathosterol concentrations were reduced
in the 10-month-old YAC128 mouse model and in knock-in mouse models carrying the CAG expansion in the
mouse HTT gene. In the knock-in mouse models, levels of brain lathosterol and cholesterol were reduced at the
symptomatic stage [44]. In contrast with their previous studies [42], levels of cholesterol and 24-HC were
found to be reduced in R6/2 mouse brain, perhaps a consequence of an age-related difference [44]. In their
most recent publication, Valenza and co-workers [45] used a heterozygous knock-in mouse model of HD car-
rying 175 CAG repeats. While lathosterol levels in the striatum were reduced (ng/mg wet weight) in these mice
at 5 (pre-motor deﬁcit), 25 (emerging motor deﬁcit) and 54 (signiﬁcant motor deﬁcit) weeks, cholesterol levels
were only reduced (mg/mg wet weight) at 54 weeks. 24-HC levels were reduced (ng/mg wet weight) at 25 and
54 weeks.
Each of the above studies [41,42,44,45] was performed by isotope-dilution GC–MS and the values reported
are for total sterols/oxysterols, i.e., the sum of esteriﬁed and non-esteriﬁed molecules (see above). This is the
common reporting format for data generated using GC–MS and in the brain, where there is very little esteriﬁed
sterol/oxysterol [46], can be assumed to be equivalent to free sterol/oxysterol concentration. This assumption
Figure 1. Structures of cholesterol, some of its precursors and some oxysterols.
Once 7α-hydroxylated, oxysterols become substrates for the enzyme HSD3B7 (3β-hydroxysteroid dehydrogenase type 7) and can be converted
from their 3β-hydroxy-5-ene to 3-oxo-4-ene forms. Shown in the red boxes are 7β,26-diHC and 26H,7O-C, assumed to be interconverted by the
HSD11B enzymes. Enzymes, supported by experimental evidence are shown in blue, where activity is assumed enzymes are in green. Diseases
resulting from enzymes deﬁciency are in red and indicated by an X preceding the disease abbreviation.
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may or may not be valid in the diseased state. 24-HC can exist as two epimers 24S-HC and 24R-HC both of
which are difﬁcult, but not impossible, to resolve by GC–MS or by LC–MS. This is probably not important for
measurements made in the brain where the 24S-HC epimer is dominating but probably is where measurements
are made in mouse plasma, where both epimers are evident [47]. Interestingly, the plasma levels of 24S-HC
(determined as the sum of non-esteriﬁed and esteriﬁed molecule by GC–MS) are reduced in patients with HD
[48,49], perhaps as a consequence of a reduced number of metabolically active neurons; however, pre-HD sub-
jects show similar plasma levels of 24S-HC to controls [48]. As mentioned above [41,42,44,45], there is some
discrepancy concerning the brain cholesterol levels in different mouse models [50]. In humans, del Toro et al.
[51] found an elevation of total cholesterol (mg/mg wet weight) in caudate, a subsection of the striatum, of
patients with HD and also R6/2 mouse, using enzymatic methods. The explanation for these discrepancies is
not obvious but may perhaps be methodological or a consequence of differences in disease progression.
Based on their cholesterol data, Valenza et al. [52] have suggested local brain supplementation of cholesterol
as a treatment for HD. They showed that nano-particle delivery of cholesterol to the brain could reduce synap-
tic and cognitive dysfunction in R6/2 HD mice [52]. Alternatively, Boussicault et al. [53] have suggested that
CYP46A1 (cytochrome P450 family 46 subfamily A member 1), the enzyme that hydroxylates cholesterol at
C-24S in the brain [2], may be therapeutic towards HD. Enhanced concentrations of CYP46A1 in neurons
should increase the rate of cholesterol metabolism and in compensation, the rate of synthesis of cholesterol
intermediates, noted to be reduced in HD mouse models. Boussicault et al. [53] eloquently demonstrated that
adeno-associated virus (AAV) delivery of CYP46A1 into the striatum of the R6/2 HD mouse model decreased
neuronal atrophy and improved motor defects and as expected increased levels of total 24-HC (ng/mg wet
weight). Levels of total desmosterol were also elevated (ng/mg wet weight), which in vitro was shown to be
Figure 2. Chromatographic separation of mono-hydroxycholesterols, extracted from mouse brain, as Girard P
derivatives demonstrating the complexity of the oxysterol proﬁle.
The different oxysterols are labelled with the location of the extra hydroxy group. No authentic standard was available for the
oxysterol indicated to be 12α-hydroxycholesterol (12α-HC). As a consequence of derivatisation, each oxysterol may give twin
peaks. The top panel shows mono-hydroxycholesterols in the brain from the Cyp27a1 knock-out mouse, the bottom panel is
from a wild-type mouse. The Cyp27a1 knock-out mouse biochemically mimics the human disorder CTX, showing an absence
of 26-HC and elevation in 7α-HC [30]. In both chromatograms, the y-axis is normalised to the most intense peak at 100%
relative abundance (RA). The measured concentration of 24S-HC corresponding to this peak is given in the right-hand corner
of each chromatogram. A hydrolysis step was not performed. To generate the reconstructed-ion chromatogram, mass
spectrometry data were recorded at high resolution with an Orbitrap analyser. Reproduced from ref. [30].
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).4
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protective towards striatal neurons expressing a polyglutamine expansion [53]. These studies suggest a potential
treatment of HD with CYP46A1 protein, or perhaps its metabolites.
Parkinson’s disease (PD): when measured as the total metabolite (sum of non-esteriﬁed and esteriﬁed),
24-HC is found to be elevated in CSF from patients with different neurodegenerative diseases [54], possibly as
a result of release from dying neuronal cells, or alternatively as a consequence of CYP46A1 metabolism of
released cholesterol from these cells. This contrasts to the situation in the circulation where total 24-HC is
reduced, probably reﬂecting a reduced number of metabolically active neurons [54]. In a recent study,
Björkhem et al. [55] found a signiﬁcant elevation in total 24-HC in CSF from a group of patients with PD
compared with a control group. Interestingly, they found a signiﬁcant correlation between 24-HC and Tau in
CSF from the PD patients. A similar correlation was observed between 24-HC and P-Thr181 Tau. Tau is a
common marker for neurodegeneration and abnormal neuronal phosphorylation leads to destabilisation and
increased levels of Tau and phospho-Tau in CSF. By clever use of the CYP46A1 overexpressing mouse, which
has an elevated level of 24-HC in the brain, they could show that 24-HC is not the likely driving force for
increased production of Tau. By investigating Tau knock-out or overexpressing mouse models, they similarly
showed that levels of Tau do not increase the production of 24-HC [55]. Interestingly, in vitro studies with
human neuroblastoma SH-SY5Y cells have shown that 24S-HC increases the levels of tyrosine hydroxylase
(TH), the rate-limiting enzyme in dopamine synthesis, while 26-HC increases levels of α-synuclein and induces
apoptosis [56]. Reduction in TH levels, accumulation of α-synuclein and apoptotic cell death are major hall-
marks of PD. Oxidative stress is a risk factor for PD and Lewy body dementia. Bosco et al. [57] found increased
levels of the cholesterol oxidation product 3β-hydroxy-5-oxo-5,6-secocholestan-6-al and its aldol in the brain of
patients with Lewy body dementia (0.21 mM cf. 0.09 mM in controls). 0.21 mM translates to 88 pg/mg. They
used chromatographic methods for quantiﬁcation and MS for identiﬁcation. As with all studies of cholesterol
metabolites which can be formed via non-enzymatic reactions, there is concern whether 3β-hydroxy-5-oxo-
5,6-secocholestan-6-al and its aldol are formed in vivo or ex vivo.
Alzheimer’s disease (AD): cholesterol has been linked to the aetiology of AD for decades with the ε4 allele of
apolipoprotein E being the most robust genetic risk factor for AD [58]. Concentrations of total 24-HC are ele-
vated in CSF of patients with AD but are reduced in their plasma/serum [54], whereas concentrations of total
26-HC have been found to be elevated in both CSF and the brain from AD patients [59]. While CYP46A1 is
normally expressed in neurons, in AD it is also expressed in astrocytes. Interestingly, one of the few factors that
inﬂuence the transcription of CYP46A1 is oxidative stress [60], perhaps as a defence mechanism against the
progression of neurodegenerative disease. Björkhem et al. [61] have suggested that the balance between 24S-HC
and 26-HC in the brain may affect the production of amyloid-β peptides in the brain and that brain permeable
26-HC may provide a missing link between hypercholesterolaemia and AD. Recent data indicate that the
26-HC metabolite 7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid is reduced in CSF from patients with AD
[62]. This may partially explain the enhanced concentration of 26-HC in AD brain being a consequence of its
reduced export through metabolism. In vivo and in vitro studies in rodents have shown that 26-HC impairs
neuronal morphology and hippocampal spine density and levels of the postsynaptic protein PSD95 [63].
PSD95 is one of the most abundant proteins in the postsynaptic density and is considered to be critical for
proper synaptic maturation and synaptic plasticity [63]. Cedazo-Minguez and co-workers [63] have suggested
inhibiting CYP27A1, the enzyme responsible for converting cholesterol to 26-HC may be a preventative strategy
to reduce the risk of dementia or to improve therapies to restore neuronal function. Signiﬁcantly, many existing
pharmaceuticals have been shown to have inhibitory effects on CYP27A1 [64], indicating potential new treat-
ments for AD.
While 26-HC and CYP27A1 may be associated with the cause of dementia, CYP46A1 may have a thera-
peutic potential towards AD. Djelti et al. [65] have shown that in the APP mouse model of AD the abundance
of amyloid-β peptides increased following inhibition of Cyp46a1 expression via AAV delivery of short hairpin
(sh) RNA directed against mouse Cyp46a1 to the hippocampus and that following treatment neuronal death
was more widespread in these mice than in normal mice. Both effects were explained by an increased choles-
terol content of neurons. In addition, when normal mice were injected with AAV-shCyp46a1, after 3 weeks
96% of CA3 neurons of the hippocampus contained phosphorylated Tau. Phosphorylated Tau was not detected
after injection of an AAV-scrambled vector [65]. AD is characterised by both amyloid and Tau pathology.
These results stimulated Burlot et al. [66] to explore the effect of AAV delivery of CYP46A1 to the hippocam-
pus of a mouse model of AD-like Tau pathology, with low levels of hippocampal 24S-HC. As expected, the
levels of 24S-HC were normalised. Remarkably, cognitive defects and spine defects characteristic of this mouse
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model were rescued. The authors suggest CYP46A1 may be a target for AD therapeutic treatment [66]. In this
regard, Pikuleva and co-workers [67] have suggested that the anti-HIV medication efavirenz, which activates
CYP46A1, could be an anti-AD treatment.
Hedgehog signalling
The Hh signalling pathway is important for developmental patterning. Mis-activation of the Hh pathway can
lead to cancers including medulloblastoma and basal cell carcinoma. In vertebrates, there are three key proteins
involved in the Hh signalling pathway, (i) Hh ligand proteins, (ii) Patched 1 (PTCH1) and (iii) SMO.
Signalling proceeds when Hh ligands relieve PTCH1 repression of SMO, allowing SMO to accumulate in cilia,
antenna-like projections on the surface of most cells, and activate GLi (glioma-associated oncogene) transcrip-
tion factors. How SMO accumulates in cilia and is activated is not yet fully understood [68].
Oxysterols, including 20S-HC and 26H,7O-C, and cholesterol, can bind to the extracellular cysteine-rich
domain (CRD) of SMO and induce Hh signalling [15,16]. To get a better understanding of the involvement of
oxysterols in the Hh signalling pathway, Raleigh et al. [17] have recently proﬁled the oxysterol content of cilia
from sea urchin embryos. Among the oxysterols enriched in cilia, they identiﬁed by LC–MS/MS (without
hydrolysis), 7-oxocholesterol (7-OC, also called 7-ketocholesterol), 7β,26-diHC, 24-oxocholesterol (24-OC, also
called 24-ketocholesterol) and 24S,25-epoxycholesterol (24S,25-EC). Both 7β,26-diHC and 24S,25-EC were
found to bind to the CRD of SMO and activate the Hh pathway [17]. Interestingly, these two oxysterols were
found to have a synergistic effect, suggesting that they may activate the pathway via multiple mechanisms. In
fact, both 24S,25-EC and 24-OC activate the Hh pathway through a second binding pocket, the cytoplasmic-
binding pocket, in SMO [17].
7-OC is well known to be converted to 7β-hydroxycholesterol (7β-HC) in a reaction catalysed by HSD11B1
(hydroxysteroid 11-β dehydrogenase 1, see Figure 1) [69–72], the enzyme that catalyses the conversion of corti-
sone to cortisol by a reduction in the 11-oxo to a 11β-hydroxy group. A pathway of bile acid biosynthesis starting
with 7-OC and 7β-HC and ending with 3β-hydroxy-7-oxochol-5-enoic acid and 3β,7β-dihydroxychol-5-enoic
acid and its N-acetylglucosamine conjugate has been suggested, with the two pathways linked by interconversion
of 7-oxo and 7β-hydroxy metabolites by HSD11B enzymes [73,74]. HSD11B2 (hydroxysteroid 11-β dehydrogen-
ase 2) is the enzyme that catalyses the oxidation of cortisol to cortisone. Interestingly, HSD11B2 is enriched in
human Hh pathway-associated medulloblastoma and Raleigh et al. [17] postulated that the Hh pathway induces
the expression of HSD11B2 which promotes SMO activity by the production of oxysterols. Importantly, depletion
of HSD11B2 via shRNAs attenuated Hh signalling in a cell model, as did the unselective HSD11B enzyme
inhibitor carbenoxolone [17].
As previous studies had shown 26H,7O-C, like 7β,26-diHC, to bind to SMO and promote its activity [15]
and as Raleigh et al. [17] showed that cells overexpressing HSD11B2 convert added 7β-HC to 7-OC, they sug-
gested a mechanism where 7β-HC is converted to 7-OC enzymatically by HSD11B2, then CYP27A1 oxidises
7-OC to 26H,7O-C and then reactive oxygen species (ROS) reduce 26H,7O-C to 7β,26-diHC. This mechanism
is perhaps a little over speculative as there appears to be no obvious source of 7β-HC to initiate the pathway
and it is not clear why ROS should reduce a 7-oxo group, by the addition of two hydrogen atoms, to a give
7β-hydroxy group. Perhaps a more likely pathway to 7β,26-diHC is through a reduction in 7-OC by HSD11B1,
then oxidation of 7β-HC by CYP27A1 [73]. Similarly, 26H,7O-C may be formed by oxidation of 7-OC by
CYP27A1 [73]. An explanation for the promotion of SMO activity by HSD11B2 would be that 26H,7O-C is a
stronger agonist to SMO than 7β,26-diHC. Whatever the mechanism for ligand formation, the discovery of
7β,26-diHC, 24-OC and 24S,25-EC as SMO agonists in cilia provides further evidence for involvement oxyster-
ols in the Hh signalling pathway.
Oxysterols and cancer
In addition to their link to mis-activation of Hh signalling and cancer, oxysterols, particularly 25-HC and
26-HC, have been linked to the aetiology of breast cancer [75–77], while metabolites of 5,6-epoxycholesterol
(5,6-EC) have been linked to both the suppression [78] and promotion of breast cancer [79]. A recent study by
Baek et al. [80] has linked 26-HC to cancer metastasis through an action on immune cells. They suggested that
metastatic effects of a high-fat diet are mediated via 26-HC and showed in an animal model that metastasis
could be reduced by ablation, or inhibition, of CYP27A1. It should be noted that their mice experiments were
performed with rather large doses of 26-HC (20 mg/g) which induced high levels of non-esteriﬁed 26-HC in
mouse plasma (0.33 mM, 134 ng/ml, measurements made in the absence of a hydrolysis step), ∼10-fold higher
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).6
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than normal levels of the non-esteriﬁed 26-HC in mouse or human [26,30] and more in keeping with the con-
centration of the sum of non-esteriﬁed and esteriﬁed molecules [26,81,82]. Baek et al. [80] also showed that the
pro-metastatic actions of polymorphonuclear-neutrophils and γδ-T cells were increased by 26-HC.
Interestingly, Soroosh et al. [83] have found 7β,26-diHC and 7α,26-dihydroxycholesterol (7α,26-diHC, also
known as 7α,27-dihydroxycholesterol) to be activators of the nuclear receptor RORγt, driving IL-17 production
in CD4+ Th17 cells as well as other IL-17-producing innate cells, such as γδ-T cells, and it is not inconceivable
that these two molecules derived through CYP27A1 oxidation of 7-hydroxy substrates may be the drivers of
the pro-metastatic actions of γδ-T cells. Similarly, as noted by Baek et al. [80], although their studies implicate
26-HC as a mediator of the pro-metastatic actions of cholesterol, the down-stream CYP27A1 metabolite
3β-HCA (Figure 1) cannot be ruled out as the bioactive metabolite. Although serum levels have been measured
for 26-HC and many other oxysterols (non-esteriﬁed plus esteriﬁed), before and during breast cancer treatment
in a small study and were, in fact, found to increase in women after receiving aromatase inhibitor treatment [81],
there is clearly a need for a large-scale study measuring both oxysterols and cholestenoic acids in serum/plasma
of breast cancer patients, to understand better the involvement of these molecules in the mechanism underlying
breast cancer metastases. Nevertheless, Baek et al. [80] showed that inhibition of CYP27A1 by the small molecule
GW273297X signiﬁcantly reduced breast cancer colonisation of the lungs in two animal models, indicating that
targeting CYP27A1 may provide a therapeutic intervention. Finally, in support of Baek’s hypothesis, it is worth
noting Borgquist et al. [84] found that taking cholesterol-lowering medication during endocrine therapy was asso-
ciated with an increase in recurrence-free survival time and distant recurrence-free interval in postmenopausal
women with early-stage hormone receptor-positive invasive breast cancer.
Perspectives
• Oxysterols were once thought of as uninteresting intermediates in bile acid synthesis pathways.
• It is now evident that oxysterols are important bioactive molecules in multiple pathways.
• It is recognised that oxysterols are ligands to nuclear receptors, can bind to GPCRs and are allosteric modulators
of NMDA receptors.
• They are also implicated as mediators of the metastatic effects of a high-fat diet and the aetiology of
neurodegeneration.
• There is a current need for accurate measurement of oxysterols and inter-laboratory comparisons to deﬁne
reference values for standard reference materials.
Abbreviations
20S-HC, 20S-hydroxycholesterol; 24-OC, 24-oxocholesterol; 24S,25-EC, 24S,25-epoxycholesterol; 24S-HC,
24S-hydroxycholesterol; 25-HC, 25-hydroxycholesterol; 3β,7α-diHCA, 3β,7α-dihydroxycholest-5-en-(25R)26-oic
acid; 3β-HCA, 3β-hydroxycholest-5-en-(25R)26-oic acid; 7-OC, 7-oxocholesterol; AAV, adeno-associated virus;
AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CRD, cysteine-rich domain; CSF, cerebrospinal
ﬂuid; CTX, cerebrotendinous xanthomatosis; EBI2, Epstein–Barr virus-induced gene 2; GC–MS, gas
chromatography–mass spectrometry; GPCR, G protein-coupled receptor; HD, Huntington’s disease; Hh,
Hedgehog; LC–MS/MS, liquid chromatography tandem–mass spectrometry; LXRs, liver X receptors; NMDA,
N-methyl-D-aspartate; PD, Parkinson’s disease; RA, relative abundance; ROS, reactive oxygen species; sh, short
hairpin; SMO, smoothened; SPG5, spastic paraplegia type 5; TH, tyrosine hydroxylase.
Funding
This work was supported by the UK Biotechnology and Biological Sciences Research Council [BBSRC, grant
numbers BB/I001735/1 and BB/N015932/1 to W.J.G., BB/L001942/1 to Y.W.].
Acknowledgements
Members of the European Network for Oxysterol Research (ENOR, https://www.oxysterols.net/) are thanked for
their informative discussions.
Competing Interests
The chromatogram presented in Figure 2 was generated exploiting Girard P derivatisation. The derivatisation
method is patented by Swansea University (US9851368B2) and licensed by Swansea Innovations to Avanti Polar
Lipids and to Cayman Chemical Company.
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 7
Biochemical Society Transactions (2019)
https://doi.org/10.1042/BST20180135
References
1 Schroepfer, Jr, G.J. (2000) Oxysterols: modulators of cholesterol metabolism and other processes. Physiol. Rev. 80, 361–554 https://doi.org/10.1152/
physrev.2000.80.1.361
2 Björkhem, I. (2007) Rediscovery of cerebrosterol. Lipids 42, 5–14 https://doi.org/10.1007/s11745-006-1003-2
3 Bauman, D.R., Bitmansour, A.D., McDonald, J.G., Thompson, B.M., Liang, G. and Russell, D.W. (2009) 25-Hydroxycholesterol secreted by macrophages
in response to Toll-like receptor activation suppresses immunoglobulin A production. Proc. Natl Acad. Sci. U.S.A. 106, 16764–16769 https://doi.org/10.
1073/pnas.0909142106
4 Blanc, M., Hsieh, W.Y., Robertson, K.A., Kropp, K.A., Forster, T., Shui, G. et al. (2013) The transcription factor STAT-1 couples macrophage synthesis of
25-hydroxycholesterol to the interferon antiviral response. Immunity 38, 106–118 https://doi.org/10.1016/j.immuni.2012.11.004
5 Chaudhuri, A.C., Harada, Y., Shimizu, K., Gut, M. and Dorfman, R.I. (1962) Biosynthesis of pregnenolone from 22-hydroxycholesterol. J. Biol. Chem.
237, 703–704 PMID:13878470
6 Vaz, F.M. and Ferdinandusse, S. (2017) Bile acid analysis in human disorders of bile acid biosynthesis. Mol. Aspects Med. 56, 10–24 https://doi.org/
10.1016/j.mam.2017.03.003
7 Fahy, E., Subramaniam, S., Brown, H.A., Glass, C.K., Merrill, Jr, A.H., Murphy, R.C. et al. (2005) A comprehensive classiﬁcation system for lipids.
J. Lipid Res. 46, 839–861 https://doi.org/10.1194/jlr.E400004-JLR200
8 Fakheri, R.J. and Javitt, N.B. (2012) 27-Hydroxycholesterol, does it exist? On the nomenclature and stereochemistry of 26-hydroxylated sterols. Steroids
77, 575–577 https://doi.org/10.1016/j.steroids.2012.02.006
9 Lehmann, J.M., Kliewer, S.A., Moore, L.B., Smith-Oliver, T.A., Oliver, B.B., Su, J.L., et al. (1997) Activation of the nuclear receptor LXR by oxysterols
deﬁnes a new hormone response pathway. J. Biol. Chem. 272, 3137–3140 https://doi.org/10.1074/jbc.272.6.3137
10 Radhakrishnan, A., Ikeda, Y., Kwon, H.J., Brown, M.S. and Goldstein, J.L. (2007) Sterol-regulated transport of SREBPs from endoplasmic reticulum to
Golgi: oxysterols block transport by binding to Insig. Proc. Natl Acad. Sci. U.S.A. 104, 6511–6518 https://doi.org/10.1073/pnas.0700899104
11 Paul, S.M., Doherty, J.J., Robichaud, A.J., Belfort, G.M., Chow, B.Y., Hammond, R.S. et al. (2013) The major brain cholesterol metabolite 24
(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors. J. Neurosci. 33, 17290–17300 https://doi.org/10.1523/
JNEUROSCI.2619-13.2013
12 Linsenbardt, A.J., Taylor, A., Emnett, C.M., Doherty, J.J., Krishnan, K., Covey, D.F. et al. (2014) Different oxysterols have opposing actions at
N-methyl-D-aspartate receptors. Neuropharmacology 85, 232–242 https://doi.org/10.1016/j.neuropharm.2014.05.027
13 Liu, C., Yang, X.V., Wu, J., Kuei, C., Mani, N.S., Zhang, L., et al. (2011) Oxysterols direct B-cell migration through EBI2. Nature 475, 519–523
https://doi.org/10.1038/nature10226
14 Hannedouche, S., Zhang, J., Yi, T., Shen, W., Nguyen, D., Pereira, J.P., et al. (2011) Oxysterols direct immune cell migration via EBI2. Nature 475,
524–527 https://doi.org/10.1038/nature10280
15 Myers, B.R., Sever, N., Chong, Y.C., Kim, J., Belani, J.D., Rychnovsky, S. et al. (2013) Hedgehog pathway modulation by multiple lipid binding sites on
the smoothened effector of signal response. Dev. Cell. 26, 346–357 https://doi.org/10.1016/j.devcel.2013.07.015
16 Byrne, E.F., Luchetti, G., Rohatgi, R. and Siebold, C. (2018) Multiple ligand binding sites regulate the hedgehog signal transducer smoothened in
vertebrates. Curr. Opin. Cell Biol. 51, 81–88 https://doi.org/10.1016/j.ceb.2017.10.004
17 Raleigh, D.R., Sever, N., Choksi, P.K., Sigg, M.A., Hines, K.M., Thompson, B.M. et al. (2018) Cilia-associated oxysterols activate smoothened. Mol. Cell.
72, 316–327.e315 https://doi.org/10.1016/j.molcel.2018.08.034
18 Schule, R., Siddique, T., Deng, H.X., Yang, Y., Donkervoort, S., Hansson, M., et al. (2010) Marked accumulation of 27-hydroxycholesterol in SPG5
patients with hereditary spastic paresis. J. Lipid Res. 51, 819–823 https://doi.org/10.1194/jlr.M002543
19 Jiang, X., Sidhu, R., Porter, F.D., Yanjanin, N.M., Speak, A.O., te Vruchte, D.T., et al. (2011) A sensitive and speciﬁc LC-MS/MS method for rapid
diagnosis of Niemann-Pick C1 disease from human plasma. J. Lipid Res. 52, 1435–1445 https://doi.org/10.1194/jlr.D015735
20 Xu, L., Korade, Z., Rosado, Jr, D.A., Liu, W., Lamberson, C.R. and Porter, N.A. (2011) An oxysterol biomarker for 7-dehydrocholesterol oxidation in cell/
mouse models for Smith-Lemli-Opitz syndrome. J. Lipid Res. 52, 1222–1233 https://doi.org/10.1194/jlr.M014498
21 Theoﬁlopoulos, S., Grifﬁths, W.J., Crick, P.J., Yang, S., Meljon, A., Ogundare, M., et al. (2014) Cholestenoic acids regulate motor neuron survival via
liver X receptors. J. Clin. Invest. 124, 4829–4842 https://doi.org/10.1172/JCI68506
22 Sidhu, R., Jiang, H., Farhat, N.Y., Carrillo-Carrasco, N., Woolery, M., Ottinger, E., et al. (2015) A validated LC-MS/MS assay for quantiﬁcation of 24
(S)-hydroxycholesterol in plasma and cerebrospinal ﬂuid. J. Lipid Res. 56, 1222–1233 https://doi.org/10.1194/jlr.D058487
23 Bleyle, L., Huidekoper, H.H., Vaz, F.M., Singh, R., Steiner, R.D. and DeBarber, A.E. (2016) Update on newborn dried bloodspot testing for
cerebrotendinous xanthomatosis: an available high-throughput liquid-chromatography tandem mass spectrometry method. Mol. Genet. Metab. Rep. 7,
11–15 https://doi.org/10.1016/j.ymgmr.2016.02.002
24 Ferdinandusse, S., Denis, S., van Roermund, C.W.T., Preece, M.A., Koster, J., Ebberink, M.S. et al. (2018) A novel case of ACOX2 deﬁciency leads to
recognition of a third human peroxisomal acyl-CoA oxidase. Biochim. Biophys. Acta 1864, 952–958 https://doi.org/10.1016/j.bbadis.2017.12.032
25 Marelli, C., Lamari, F., Rainteau, D., Lafourcade, A., Banneau, G., Humbert, L. et al. (2018) Plasma oxysterols: biomarkers for diagnosis and treatment
in spastic paraplegia type 5. Brain 141, 72–84 https://doi.org/10.1093/brain/awx297
26 Dzeletovic, S., Breuer, O., Lund, E. and Diczfalusy, U. (1995) Determination of cholesterol oxidation products in human plasma by isotope dilution-mass
spectrometry. Anal. Biochem. 225, 73–80 https://doi.org/10.1006/abio.1995.1110
27 Schött, H.F. and Lütjohann, D. (2015) Validation of an isotope dilution gas chromatography-mass spectrometry method for combined analysis of
oxysterols and oxyphytosterols in serum samples. Steroids 99, 139–150 https://doi.org/10.1016/j.steroids.2015.02.006
28 Stiles, A.R., Kozlitina, J., Thompson, B.M., McDonald, J.G., King, K.S. and Russell, D.W. (2014) Genetic, anatomic, and clinical determinants of human
serum sterol and vitamin D levels. Proc. Natl Acad. Sci. U.S.A. 111, E4006–E4014 https://doi.org/10.1073/pnas.1413561111
29 Roberg-Larsen, H., Lund, K., Vehus, T., Solberg, N., Vesterdal, C., Misaghian, D., et al. (2014) Highly automated nano-LC/MS-based approach for
thousand cell-scale quantiﬁcation of side chain-hydroxylated oxysterols. J. Lipid Res. 55, 1531–1536 https://doi.org/10.1194/jlr.D048801
30 Grifﬁths, W.J., Crick, P.J., Meljon, A., Theoﬁlopoulos, S., Abdel-Khalik, J., Yutuc, E., et al. (2019) Additional pathways of sterol metabolism: evidence
from analysis of Cyp27a1−/− mouse brain and plasma. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1864, 191–211 https://doi.org/10.1016/j.bbalip.
2018.11.006
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).8
Biochemical Society Transactions (2019)
https://doi.org/10.1042/BST20180135
31 Dias, I.H.K., Wilson, S.R. and Roberg-Larsen, H. (2018) Chromatography of oxysterols. Biochimie 153, 3–12 https://doi.org/10.1016/j.biochi.2018.05.004
32 Abdel-Khalik, J., Yutuc, E., Crick, P.J., Gustafsson, J.A., Warner, M., Roman, G., et al. (2017) Defective cholesterol metabolism in amyotrophic lateral
sclerosis. J. Lipid Res. 58, 267–278 https://doi.org/10.1194/jlr.P071639
33 Crick, P.J., Grifﬁths, W.J., Zhang, J., Beibel, M., Abdel-Khalik, J., Kuhle, J. et al. (2017) Reduced plasma levels of 25-hydroxycholesterol and increased
cerebrospinal ﬂuid levels of bile acid precursors in multiple sclerosis patients. Mol. Neurobiol. 54, 8009–8020 https://doi.org/10.1007/
s12035-016-0281-9
34 Diekstra, F.P., Saris, C.G., van Rheenen, W., Franke, L., Jansen, R.C., van Es, M.A., et al. (2012) Mapping of gene expression reveals CYP27A1 as a
susceptibility gene for sporadic ALS. PLoS ONE 7, e35333 https://doi.org/10.1371/journal.pone.0035333
35 Schöls, L., Rattay, T.W., Martus, P., Meisner, C., Baets, J., Fischer, I., et al. (2017) Hereditary spastic paraplegia type 5: natural history, biomarkers and
a randomized controlled trial. Brain 140, 3112–3127 https://doi.org/10.1093/brain/awx273
36 Vilarinho, S., Sari, S., Mazzacuva, F., Bilgüvar, K., Esendagli-Yilmaz, G., Jain, D. et al. (2016) ACOX2 deﬁciency: a disorder of bile acid synthesis with
transaminase elevation, liver ﬁbrosis, ataxia, and cognitive impairment. Proc. Natl Acad. Sci. U.S.A. 113, 11289–11293 https://doi.org/10.1073/pnas.
1613228113
37 Monte, M.J., Alonso-Peña, M., Briz, O., Herraez, E., Berasain, C., Argemi, J. et al. (2017) ACOX2 deﬁciency: an inborn error of bile acid synthesis
identiﬁed in an adolescent with persistent hypertransaminasemia. J. Hepatol. 66, 581–588 https://doi.org/10.1016/j.jhep.2016.11.005
38 Iuliano, L., Crick, P.J., Zerbinati, C., Tritapepe, L., Abdel-Khalik, J., Poirot, M. et al. (2015) Cholesterol metabolites exported from human brain. Steroids
99, 189–193 https://doi.org/10.1016/j.steroids.2015.01.026
39 Saeed, A.A., Edström, E., Pikuleva, I., Eggertsen, G. and Björkhem, I. (2017) On the importance of albumin binding for the ﬂux of
7α-hydroxy-3-oxo-4-cholestenoic acid in the brain. J. Lipid Res. 58, 455–459 https://doi.org/10.1194/jlr.P073403
40 Bates, G.P., Dorsey, R., Gusella, J.F., Hayden, M.R., Kay, C., Leavitt, B.R., et al. (2015) Huntington disease. Nat. Rev. Dis. Primers 1, 15005
https://doi.org/10.1038/nrdp.2015.5
41 Valenza, M., Carroll, J.B., Leoni, V., Bertram, L.N., Björkhem, I., Singaraja, R.R., et al. (2007) Cholesterol biosynthesis pathway is disturbed in YAC128
mice and is modulated by huntingtin mutation. Hum. Mol. Genet. 16, 2187–2198 https://doi.org/10.1093/hmg/ddm170
42 Valenza, M., Leoni, V., Tarditi, A., Mariotti, C., Björkhem, I., Di Donato, S. et al. (2007) Progressive dysfunction of the cholesterol biosynthesis pathway
in the R6/2 mouse model of Huntington’s disease. Neurobiol. Dis. 28, 133–142 https://doi.org/10.1016/j.nbd.2007.07.004
43 Sipione, S., Rigamonti, D., Valenza, M., Zuccato, C., Conti, L., Pritchard, J. et al. (2002) Early transcriptional proﬁles in huntingtin-inducible striatal cells
by microarray analyses. Hum. Mol. Genet. 11, 1953–1965 https://doi.org/10.1093/hmg/11.17.1953
44 Valenza, M., Leoni, V., Karasinska, J.M., Petricca, L., Fan, J., Carroll, J., et al. (2010) Cholesterol defect is marked across multiple rodent models of
Huntington’s disease and is manifest in astrocytes. J. Neurosci. 30, 10844–10850 https://doi.org/10.1523/JNEUROSCI.0917-10.2010
45 Shankaran, M., Di Paolo, E., Leoni, V., Caccia, C., Ferrari Bardile, C., Mohammed, H. et al. (2017) Early and brain region-speciﬁc decrease of de novo
cholesterol biosynthesis in Huntington’s disease: a cross-validation study in Q175 knock-in mice. Neurobiol. Dis. 98, 66–76 https://doi.org/10.1016/j.
nbd.2016.11.013
46 Dietschy, J.M. and Turley, S.D. (2004) Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early
development and in the mature animal. J. Lipid Res. 45, 1375–1397 https://doi.org/10.1194/jlr.R400004-JLR200
47 Saeed, A.A., Genové, G., Li, T., Lütjohann, D., Olin, M., Mast, N., et al. (2014) Effects of a disrupted blood-brain barrier on cholesterol homeostasis in
the brain. J. Biol. Chem. 289, 23712–23722 https://doi.org/10.1074/jbc.M114.556159
48 Leoni, V., Mariotti, C., Tabrizi, S.J., Valenza, M., Wild, E.J., Henley, S.M. et al. (2008) Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest
and early Huntington’s disease. Brain 131, 2851–2859 https://doi.org/10.1093/brain/awn212
49 Leoni, V., Long, J.D., Mills, J.A., Di Donato, S. and Paulsen, J.S. and PREDICT-H.D Study Group. (2013) Plasma 24S-hydroxycholesterol correlation with
markers of Huntington disease progression. Neurobiol. Dis. 55, 37–43 https://doi.org/10.1016/j.nbd.2013.03.013
50 Marullo, M., Valenza, M., Leoni, V., Caccia, C., Scarlatti, C., De Mario, A., et al. (2012) Pitfalls in the detection of cholesterol in Huntington’s disease
models. PLoS Curr. 4, e505886e505889a501968 PMID:23145355
51 del Toro, D., Xifró, X., Pol, A., Humbert, S., Saudou, F., Canals, J.M. et al. (2010) Altered cholesterol homeostasis contributes to enhanced excitotoxicity
in Huntington’s disease. J. Neurochem. 115, 153–167 https://doi.org/10.1111/j.1471-4159.2010.06912.x
52 Valenza, M., Chen, J.Y., Di Paolo, E., Ruozi, B., Belletti, D., Ferrari Bardile, C., et al. (2015) Cholesterol-loaded nanoparticles ameliorate synaptic and
cognitive function in Huntington’s disease mice. EMBO Mol. Med. 7, 1547–1564 https://doi.org/10.15252/emmm.201505413
53 Boussicault, L., Alves, S., Lamazière, A., Planques, A., Heck, N., Moumné, L., et al. (2016) CYP46A1, the rate-limiting enzyme for cholesterol
degradation, is neuroprotective in Huntington’s disease. Brain 139, 953–970 https://doi.org/10.1093/brain/awv384
54 Björkhem, I., Cedazo-Minguez, A., Leoni, V. and Meaney, S. (2009) Oxysterols and neurodegenerative diseases. Mol. Aspects Med. 30, 171–179
https://doi.org/10.1016/j.mam.2009.02.001
55 Björkhem, I., Patra, K., Boxer, A.L. and Svenningsson, P. (2018) 24S-Hydroxycholesterol correlates with tau and is increased in cerebrospinal ﬂuid in
Parkinson’s disease and corticobasal syndrome. Front. Neurol. 9, 756 https://doi.org/10.3389/fneur.2018.00756
56 Rantham Prabhakara, J.P., Feist, G., Thomasson, S., Thompson, A., Schommer, E. and Ghribi, O. (2008) Differential effects of 24-hydroxycholesterol
and 27-hydroxycholesterol on tyrosine hydroxylase and α-synuclein in human neuroblastoma SH-SY5Y cells. J. Neurochem. 107, 1722–1729
https://doi.org/10.1111/j.1471-4159.2008.05736.x
57 Bosco, D.A., Fowler, D.M., Zhang, Q., Nieva, J., Powers, E.T., Wentworth, Jr, P. et al. (2006) Elevated levels of oxidized cholesterol metabolites in Lewy
body disease brains accelerate α-synuclein ﬁbrilization. Nat. Chem. Biol. 2, 249–253 https://doi.org/10.1038/nchembio782
58 Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., et al. (1993) Gene dose of apolipoprotein E type 4 allele
and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923 https://doi.org/10.1126/science.8346443
59 Heverin, M., Bogdanovic, N., Lutjohann, D., Bayer, T., Pikuleva, I., Bretillon, L. et al. (2004) Changes in the levels of cerebral and extracerebral sterols in
the brain of patients with Alzheimer’s disease. J. Lipid Res. 45, 186–193 https://doi.org/10.1194/jlr.M300320-JLR200
60 Ohyama, Y., Meaney, S., Heverin, M., Ekström, L., Brafman, A., Shaﬁr, M., et al. (2006) Studies on the transcriptional regulation of cholesterol
24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes. J. Biol. Chem. 281, 3810–3820 https://doi.org/10.1074/jbc.
M505179200
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 9
Biochemical Society Transactions (2019)
https://doi.org/10.1042/BST20180135
61 Björkhem, I., Heverin, M., Leoni, V., Meaney, S. and Diczfalusy, U. (2006) Oxysterols and Alzheimer’s disease. Acta Neurol. Scand. Suppl. 185, 43–49
https://doi.org/10.1111/j.1600-0404.2006.00684.x
62 Grifﬁths, W.J., Abdel-Khalik, J., Yutuc, E., Roman, G., Warner, M., Gustafsson, J.A. et al. (2018) Concentrations of bile acid precursors in cerebrospinal
ﬂuid of Alzheimer’s disease patients. Free Radic. Biol. Med. 134, 42–52 https://doi.org/10.1016/j.freeradbiomed.2018.12.020
63 Merino-Serrais, P., Loera-Valencia, R., Rodriguez-Rodriguez, P., Parrado-Fernandez, C., Ismail, M.A., Maioli, S., et al. (2019) 27-Hydroxycholesterol
induces aberrant morphology and synaptic dysfunction in hippocampal neurons. Cereb. Cortex 29, 429–446 https://doi.org/10.1093/cercor/bhy274
64 Lam, M., Mast, N. and Pikuleva, I.A. (2018) Drugs and scaffold that inhibit cytochrome P450 27A1 in vitro and in vivo. Mol. Pharmacol. 93, 101–108
https://doi.org/10.1124/mol.117.110742
65 Djelti, F., Braudeau, J., Hudry, E., Dhenain, M., Varin, J., Bièche, I., et al. (2015) CYP46A1 inhibition, brain cholesterol accumulation and
neurodegeneration pave the way for Alzheimer’s disease. Brain 138, 2383–2398 https://doi.org/10.1093/brain/awv166
66 Burlot, M.A., Braudeau, J., Michaelsen-Preusse, K., Potier, B., Ayciriex, S., Varin, J., et al. (2015) Cholesterol 24-hydroxylase defect is implicated in
memory impairments associated with Alzheimer-like Tau pathology. Hum. Mol. Genet. 24, 5965–5976 https://doi.org/10.1093/hmg/ddv268
67 Mast, N., Saadane, A., Valencia-Olvera, A., Constans, J., Maxﬁeld, E., Arakawa, H. et al. (2017) Cholesterol-metabolizing enzyme cytochrome P450
46A1 as a pharmacologic target for Alzheimer’s disease. Neuropharmacology 123, 465–476 https://doi.org/10.1016/j.neuropharm.2017.06.026
68 Briscoe, J. and Thérond, P.P. (2013) The mechanisms of Hedgehog signalling and its roles in development and disease. Nat. Rev. Mol. Cell Biol. 14,
416–429 https://doi.org/10.1038/nrm3598
69 Schweizer, R.A., Zürcher, M., Balazs, Z., Dick, B. and Odermatt, A. (2004) Rapid hepatic metabolism of 7-ketocholesterol by 11β-hydroxysteroid
dehydrogenase type 1: species-speciﬁc differences between the rat, human, and hamster enzyme. J. Biol. Chem. 279, 18415–18424 https://doi.org/
10.1074/jbc.M313615200
70 Hult, M., Elleby, B., Shafqat, N., Svensson, S., Rane, A., Jörnvall, H. et al. (2004) Human and rodent type 1 11β-hydroxysteroid dehydrogenases are
7β-hydroxycholesterol dehydrogenases involved in oxysterol metabolism. Cell. Mol. Life Sci. 61, 992–999 https://doi.org/10.1007/s00018-003-3476-y
71 Larsson, H., Böttiger, Y., Iuliano, L. and Diczfalusy, U. (2007) In vivo interconversion of 7β-hydroxycholesterol and 7-ketocholesterol, potential surrogate
markers for oxidative stress. Free Radic. Biol. Med. 43, 695–701 https://doi.org/10.1016/j.freeradbiomed.2007.04.033
72 Cobice, D.F., Mackay, C.L., Goodwin, R.J., McBride, A., Langridge-Smith, P.R., Webster, S.P. et al. (2013) Mass spectrometry imaging for dissecting
steroid intracrinology within target tissues. Anal. Chem. 85, 11576–11584 https://doi.org/10.1021/ac402777k
73 Wang, Y. and Grifﬁths, W.J. (2018) Unravelling new pathways of sterol metabolism: lessons learned from in-born errors and cancer. Curr. Opin. Clin.
Nutr. Metab. Care 21, 90–96 https://doi.org/10.1097/MCO.0000000000000442
74 Grifﬁths, W.J., Gilmore, I., Yutuc, E., Abdel-Khalik, J., Crick, P.J., Hearn, T., et al. (2018) Identiﬁcation of unusual oxysterols and bile acids with 7-oxo or
3β,5α,6β-trihydroxy functions in human plasma by charge-tagging mass spectrometry with multistage fragmentation. J. Lipid Res. 59, 1058–1070
https://doi.org/10.1194/jlr.D083246
75 Nelson, E.R., Wardell, S.E., Jasper, J.S., Park, S., Suchindran, S., Howe, M.K., et al. (2013) 27-Hydroxycholesterol links hypercholesterolemia and
breast cancer pathophysiology. Science 342, 1094–1098 https://doi.org/10.1126/science.1241908
76 Wu, Q., Ishikawa, T., Sirianni, R., Tang, H., McDonald, J.G., Yuhanna, I.S., et al. (2013) 27-Hydroxycholesterol promotes cell-autonomous, ER-positive
breast cancer growth. Cell Rep. 5, 637–645 https://doi.org/10.1016/j.celrep.2013.10.006
77 Simigdala, N., Gao, Q., Pancholi, S., Roberg-Larsen, H., Zvelebil, M., Ribas, R., et al. (2016) Cholesterol biosynthesis pathway as a novel mechanism of
resistance to estrogen deprivation in estrogen receptor-positive breast cancer. Breast Cancer Res. 18, 58 https://doi.org/10.1186/s13058-016-0713-5
78 Segala, G., David, M., de Medina, P., Poirot, M.C., Serhan, N., Vergez, F., et al. (2017) Dendrogenin A drives LXR to trigger lethal autophagy in
cancers. Nat. Commun. 8, 1903 https://doi.org/10.1038/s41467-017-01948-9
79 Voisin, M., de Medina, P., Mallinger, A., Dalenc, F., Huc-Claustre, E., Leignadier, J., et al. (2017) Identiﬁcation of a tumor-promoter cholesterol
metabolite in human breast cancers acting through the glucocorticoid receptor. Proc. Natl Acad. Sci. U.S.A. 114, E9346–E9355 https://doi.org/10.
1073/pnas.1707965114
80 Baek, A.E., Yu, Y.A., He, S., Wardell, S.E., Chang, C.Y., Kwon, S., et al. (2017) The cholesterol metabolite 27 hydroxycholesterol facilitates breast
cancer metastasis through its actions on immune cells. Nat. Commun. 8, 864 https://doi.org/10.1038/s41467-017-00910-z
81 Dalenc, F., Iuliano, L., Filleron, T., Zerbinati, C., Voisin, M., Arellano, C., et al. (2017) Circulating oxysterol metabolites as potential new surrogate
markers in patients with hormone receptor-positive breast cancer: results of the OXYTAM study. J. Steroid Biochem. Mol. Biol. 169, 210–218
https://doi.org/10.1016/j.jsbmb.2016.06.010
82 Karuna, R., Holleboom, A.G., Motazacker, M.M., Kuivenhoven, J.A., Frikke-Schmidt, R., Tybjaerg-Hansen, A. et al. (2011) Plasma levels of
27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism. Atherosclerosis 214, 448–455
https://doi.org/10.1016/j.atherosclerosis.2010.10.042
83 Soroosh, P., Wu, J., Xue, X., Song, J., Sutton, S.W., Sablad, M., et al. (2014) Oxysterols are agonist ligands of RORγt and drive Th17 cell
differentiation. Proc. Natl Acad. Sci. U.S.A. 111, 12163–12168 https://doi.org/10.1073/pnas.1322807111
84 Borgquist, S., Giobbie-Hurder, A., Ahern, T.P., Garber, J.E., Colleoni, M., Láng, I., et al. (2017) Cholesterol, cholesterol-lowering medication use, and
breast cancer outcome in the BIG 1-98 study. J. Clin. Oncol. 35, 1179–1188 https://doi.org/10.1200/JCO.2016.70.3116
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).10
Biochemical Society Transactions (2019)
https://doi.org/10.1042/BST20180135
